<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03849378</url>
  </required_header>
  <id_info>
    <org_study_id>02-2018-002</org_study_id>
    <nct_id>NCT03849378</nct_id>
  </id_info>
  <brief_title>Effects of Sargassum Horneri Extract on Patients With Hypersensitivity</brief_title>
  <official_title>Effects of Sargassum Horneri Extract on Patients With Hypersensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate
      the effects of Sargassum Horneri Extract in patients with skin hypersensitivity for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies have indicated that Panax Ginseng C.A. Mey Extract may have the ability to
      improve liver function. Therefore, the investigators conduct a randomized, double-blind,
      placebo-controlled study to investigate the effects of the Sargassum Horneri Extract in
      patients with skin hypersensitivity for 12 weeks; the safety of the compound are also
      evaluate. The Investigators examine SCORAD(SCORing of Atopic Dermatitis) score, PGA (Patient
      Global assessment) score, IGA (Investigator Global assessment) score, total IgE, eosinophil
      counts, ECP, IL-4, IL-31, and TARC at baseline, as well as after 6 and 12 weeks of
      intervention. One hundred adults were administered either 1,000 mg of Sargassum Horneri
      Extract or a placebo each day for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCORing of Atopic Dermatitis (SCORAD) total score</measure>
    <time_frame>Change from Baseline SCORAD total score at 3 months</time_frame>
    <description>Change in SCORAD total score during 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global assessment (PGA) score</measure>
    <time_frame>Change from Baseline PGA score at 3 months</time_frame>
    <description>Change in PGA score during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global assessment (IGA) score</measure>
    <time_frame>Change from Baseline IGA score at 3 months</time_frame>
    <description>Change in IGA score during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Immunoglobulin E (IgE)</measure>
    <time_frame>Change from Baseline total IgE (IU/mL) level at 3 months</time_frame>
    <description>Change in total IgE (IU/mL) level during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil counts</measure>
    <time_frame>Change from Baseline eosinophil counts (/uL) at 3 months</time_frame>
    <description>Change in eosinophil counts (/uL) during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil cationic protein (ECP)</measure>
    <time_frame>Change from Baseline ECP (μg/L) level at 3 months</time_frame>
    <description>Change in ECP (μg/L) level during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-4 (IL-4)</measure>
    <time_frame>Change from Baseline IL-4 (ng/mL) level at 3 months</time_frame>
    <description>Change in IL-4 (ng/mL) level during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-31 (IL-31)</measure>
    <time_frame>Change from Baseline IL-31 (ng/mL) level at 3 months</time_frame>
    <description>Change in IL-31 (ng/mL) level during 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thymus- and activation-regulated chemokine (TARC)</measure>
    <time_frame>Change from Baseline TARC (pg/mL) level at 3 months</time_frame>
    <description>Change in TARC (pg/mL) level during 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Skin Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Sargassum Horneri Extract group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes Sargassum Horneri Extract for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group takes Placebo Extract for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sargassum Horneri Extract group</intervention_name>
    <description>This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.</description>
    <arm_group_label>Sargassum Horneri Extract group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>This group takes 1,000 mg/day of Placebo Extract for 12 weeks.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopy by Hanifin &amp; Rajka diagnostic criteria

          -  SCORAD &lt; 40

        Exclusion Criteria:

          -  Abnormal liver or renal function (i.e., serum aminotransferase activity &gt; 3 times of
             upper limit of reference range and serum creatinine concentrations &gt; 1.2 mg/dL)

          -  Diabetes (diagnosed clinically or fasting glucose level &gt; 126 mg/dL)

          -  History of viral hepatitis or cancer

          -  Uncontrolled hypertension

          -  History of serious cardiac disease such as angina or myocardial infarction

          -  History of gastrectomy

          -  History of medication for psychiatric disease

          -  Administration of oriental medicine including herbs within the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Yeoup Lee</last_name>
    <phone>360-2860</phone>
    <phone_ext>055</phone_ext>
    <email>saylee@pnu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Li Lee</last_name>
    <phone>360-2860</phone>
    <phone_ext>055</phone_ext>
    <email>yeri1230@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Yeoup Lee, Pf.</last_name>
      <phone>82-55-360-2860</phone>
      <email>saylee@pnu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

